It’s the EMVS’s Birthday! The European Medicines Verification System’s third anniversaryExecutive summaryToday marks the third anniversary of the European Medicines Verification (“EMVS”) System Go-live. This unique system ensures patient safety by detecting falsified...
Value added Medicines | Online SummitExecutive summaryEmpowering the healthcarecommunity by improvingexisting treatments• Innovating on existing molecules in the form of repurposing,reformulation and combination of therapies has the potential to delivertimely and...
Háziorvosok is felírhatják a favipiravirt COVID-19-betegeknekAkadémikusok javaslatára Mit kell tudni a gyógyszerről és milyen esetekben alkalmazható? Erről nyilatkozott az mta.hu-nak Keserű György Miklós akadémikus, a Természettudományi Kutatóközpont Gyógyszerkémiai...
The recently published EU pharmaceutical strategy is a welcome tool to address public health challenges in Europe, including equitable access to medicines, reducing medicines shortages, and supporting secure supply chains. At the foundation of addressing these issues is a robust and agile regulatory system. The EU regulatory network, the European Medicines Agency (EMA) and national counterparts, is among the most advanced system worldwide, but still has room for greater efficiency.
The EMA has great inroads to make to embrace the digital era and leave behind burdensome paperwork and processes.
Practical digital infrastructures like an electronic patient information (ePI) leaflet can be easily implemented and benefit the entire health community: patients can access readable and up to date information on their medicines, as can the healthcare professionals who manage their treatment pathways. A more digitalised network can also be more responsive to tackling medicines shortages, by collating harmonised data on medicines availability, in real time. For this, an inter-connected EU-national digital portal must be developed for the system to be efficient.
The outbreak of COVID-19 exposed the scope for improvements in the regulatory system, as unprecedented flexibilities allowed countries and industry to allocate urgent supplies of medicines to hospitals across Europe. While these flexibilities proved invaluable during a crisis, we should not overlook the benefits of a more agile regulatory system.
Commenting at the Medicines for Europe Regulatory Affairs webinar series, association President Christoph Stoller (Teva) said
“We cannot miss the opportunity to implement the hard-learned lessons of the pandemic and make our systems more resilient and responsive in the future. The EU pharma strategy paves the way to improve the regulatory network, making it more digital, connected, and agile. Practical tools like an e-leaflet for medicines or a common digital shortage reporting system have benefits in times of crisis but also well beyond. We count on our partners in the European Medicines Agency and the health policy network to work together with us to find workable solutions, that not only give more competence to the agencies, but also enhance the way of operating.”
Forrás: Medicines for Europe